<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105595</url>
  </required_header>
  <id_info>
    <org_study_id>2019.8408</org_study_id>
    <nct_id>NCT04105595</nct_id>
  </id_info>
  <brief_title>Post Market Registry of the CBSO</brief_title>
  <acronym>CBSO Registry</acronym>
  <official_title>Multi Centre, International, Post Market Registry to Monitor the Clinical Performance and Safety of an Atrial Septal Closure Device With Bioresorbable Framework in Patients With Clinically Significant Atrial Septum Defect (ASD) or Patent Foramen Ovale (PFO) in Routine Clinical Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carag AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carag AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi centre, international, post market registry to monitor the clinical performance and
      safety of an atrial septal closure device with biodegradable framework in patients with
      clinically significant atrial septum defect (ASD) or patent foramen ovale (PFO) in routine
      clinical use
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Effective closure by echocardiography</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety throughout the follow up duration by absence of serious incidents</measure>
    <time_frame>day 0 to 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Septal Defect</condition>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>ASD patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>PFO patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Septal defect closure</intervention_name>
    <description>Device closure of atrial septal defect</description>
    <arm_group_label>ASD patients</arm_group_label>
    <arm_group_label>PFO patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Intent to treat population: All enrolled patients Modified Intent to Treat population: All
        enrolled patients who have a permanently implanted CBSO.

        Per Protocol population: All patients in the enrolled population who have a permanently
        implanted CBSO and do not have a major protocol deviation. The per protocol population will
        be used as the final population for analysis.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient suffers from ASD (including ostium secundum ASD or a fenestration from a
             Fontan procedure) or PFO and is planned to receive the CBSO.

          -  Patient (or legal guardian) has been informed and agreed to and signed the informed
             consent form.

          -  A CBSO is implanted into the patient.

        Exclusion Criteria:

          -  Patient is known to have one or more of the contraindications listed in the
             instructions for use.

          -  Patient is currently participating in one or more interventional studies, with
             exception of a study investigating the CBSO.

          -  Patient is implanted with another product in the atrial septum.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

